SAN DIEGO, April 9, 2008 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (Amex: ANX) announced today that it has appointed
Jose Hechavarria to the new position of vice president of manufacturing.
Mr. Hechavarria will be responsible for leading the company's planned
commercial manufacturing operations.
"We are pleased to have recruited Jose to our team," said Evan M.
Levine, ADVENTRX chief executive officer. "He brings experience and
leadership in the drug manufacturing and quality arena, and we believe his
expertise will be especially valuable as we continue to develop the
commercial manufacturing processes for both ANX-530 (vinorelbine emulsion)
and ANX-514 (docetaxel emulsion)."
Mr. Hechavarria has over 30 years of experience in the pharmaceutical
industry and has overseen all aspects of third-party contract
manufacturing. He has held various senior positions at companies including
Bristol-Myers Squibb, Dupont Pharmaceuticals, DuPont Merck Pharmaceutical
Company as well as the New England Nuclear Corporation. Mr. Hechavarria
holds a B.S. in chemical technology from the University of Lowell, an A.S.
in nuclear engineering technology from the Wentworth Institute, and has
completed post graduate training in parenteral therapeutics agents at the
University of Tennessee College of Pharmacy.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on
in-licensing, developing and commercializing proprietary product candidates
primarily for the treatment of cancer and infectious disease. The Company
seeks to improve the performance and commercial potential of existing
treatments by addressing problems associated with these treatment regimens.
More information can be found on ADVENTRX's web site at
http://www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other factors
that, if they do not materialize or prove to be accurate, could cause
ADVENTRX's results to differ materially from historical results or those
expressed or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that ADVENTRX will
be unable to raise sufficient capital to fund the projects necessary to
meet its anticipated or stated goals and milestones; the risk that
preclinical results are not indicative of the success of subsequent
clinical trials and the results of pending clinical trials; the potential
for ADVENTRX's product candidates to receive regulatory approval for one or
more indications on a timely basis or at all, and the uncertain process of
seeking regulatory approval; other difficulties or delays in developing,
testing, manufacturing, marketing and obtaining regulatory approval for
ADVENTRX's product candidates; the potential for regulatory authorities to
require additional preclinical work or other clinical requirements to
support regulatory filings; the market potential for ADVENTRX's product
candidates and ADVENTRX's ability to compete in those markets; the scope
and validity of patent protection for ADVENTRX's product candidates; patent
and non-patent exclusivity covering Navelbine(R) and Taxotere(R); and other
risks and uncertainties more fully described in ADVENTRX's press releases
and periodic filings with the Securities and Exchange Commission.
ADVENTRX's public filings with the Securities and Exchange Commission are
available at http://www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date when made. ADVENTRX does not
intend to revise or update any forward-looking statement as set forth in
this press release to reflect events or circumstances arising after the
date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
 back to top
Related links:
http://www.adventrx.com
CONTACT:
investors, Ioana C. Hone of ADVENTRX
Pharmaceuticals, Inc., +1-858-552-0866
|
